• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biomarin Pharmaceuticals (NQ: BMRN )

    83.34 -1.32 (-1.56%)
    Official Closing Price Updated: 4:15 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,312,663
    Open 84.83
    Bid (Size) 72.11 (2)
    Ask (Size) 85.18 (1)
    Prev. Close 84.66
    Today's Range 83.32 - 86.24
    52wk Range 73.67 - 99.56
    Shares Outstanding 183,352,255
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    $100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
    Via Benzinga
    $1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today
    Via Benzinga

    Performance

    YTD
    -15.00%
    -15.00%
    1 Month
    -1.98%
    -1.98%
    3 Month
    -7.88%
    -7.88%
    6 Month
    -10.80%
    -10.80%
    1 Year
    -3.41%
    -3.41%

    More News

    Read More
    Peering Into Biomarin Pharmaceutical's Recent Short Interest
    Via Benzinga
    Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced.
    Via Chartmill
    Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
    Via Benzinga
    For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
    Via Chartmill
    Looking Into Biomarin Pharmaceutical's Recent Short Interest
    Via Benzinga
    NASDAQ:BMRN is not too expensive for the growth it is showing.
    Via Chartmill
    Analyst Ratings For Biomarin Pharmaceutical
    Via Benzinga
    (BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
    Via Benzinga
    CrowdStrike, KKR, GoDaddy To Join S&P 500 In Quarterly Rebalance; Stocks Jump
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
    Via InvestorPlace
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
    Via Benzinga
    BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results
    Via Investor's Business Daily
    Li Auto Was One Of The Worst-Performing Stocks Last Week: Are These 10 Large-Cap Stocks Losers In Your Portfolio? (May 12-May 18, 2024)
    Via Benzinga
    4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
    Via The Motley Fool
    Topics Stocks
    Exposures US Equities
    Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    The 3 Best Biotech Stocks to Buy in May 2024
    Via InvestorPlace
    Citi Just Cut Its Price Target on These 3 Stocks
    Via InvestorPlace
    For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
    Via Chartmill
    4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
    Via The Motley Fool
    Topics Stocks
    Exposures US Equities
    Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.